Fierce Pharma May 28, 2024
Bolstered by a full FDA approval for its primary immunoglobulin A nephropathy (IgAN) treatment Tarpeyo, Calliditas has earned the attention of Japanese chemical giant Asahi Kasei.
Asahi has made a cash offer to acquire Sweden’s Calliditas in a deal worth 11.16 billion Swedish crowns ($1.06 billion), the companies announced Tuesday.
The proposal has already won the blessing of three of the Swedish drugmaker’s biggest stakeholders—BVF Partners, Linc AB and Stiftelsen Industrifonden—plus “other large securityholders,” Calliditas explained in a release.
An acceptance period for the offer is expected to commence on or around July 18 and expire around August 30, the companies added.
Asahi’s bid for Calliditas represents a 74% premium to the company’s closing U.S. share price of $22.42...
Today's Sponsors
Today's Sponsor